Contact HealthDay
Tel: 203.855.1400 or E-mail

News By Specialty

Allergy
Anesthesiology
Cardiology
Cosmetic Surgery
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Practice
Gastroenterology
Geriatrics
Hematology & Oncology
HIV & AIDS
Infectious Disease
Internal Medicine
Nephrology
Neurology
Nursing
OBGYN & Women's Health
Ophthalmology
Orthopedics
Otolaryngology
Pain Management
Pathology
Pediatrics
Pharmacy
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Follow us on:

    


e-Healthcare Leadership Awards


Iron Status Predicts Prognosis in Patients With T2DM, CAD
Low and high serum ferritin, high serum soluble transferrin receptor levels predict poor prognosis

TUESDAY, Nov. 5 (HealthDay News) -- Iron status can independently predict long-term outcomes in patients with type 2 diabetes and coronary artery disease (CAD), according to a study published online Oct. 15 in Diabetes Care.

Beata Ponikowska, M.D., Ph.D., from Wroclaw Medical University in Poland, and colleagues measured serum ferritin, transferrin saturation, and soluble transferrin receptor (sTfR) in 287 patients with type 2 diabetes and stable CAD (average age, 65 years; 78 percent men). Participants were followed for a mean of 45 months.

The researchers found that, during the study period, 21 percent of patients died and 21 percent had cardiovascular hospitalizations. The five-year all-cause mortality rates were strongly predicted by both serum ferritin and sTfR, independent of other variables (including hemoglobin, measures of renal function, inflammation, and neurohormonal activation). The relationship between sTfR and mortality was exponential (adjusted hazard ratio [HR] per 1 log mg/L, 4.24; P = 0.01), while a U-shaped relationship was seen for ferritin and mortality (for the lowest and the highest quintiles versus the middle quintile, respectively: adjusted HRs, 7.18 and 5.12).

"Both low and high serum ferritin (possibly reflecting depleted and excessive iron stores, respectively) along with high serum sTfR (reflecting reduced metabolically available iron) identify patients with type 2 diabetes and CAD who have a poor prognosis," the authors conclude.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.

August 1, 2014

Archive Search

By Keyword:
By Category:
By Topic:

Related Articles

Jump in Doctor's Office Visits for Young Adults With Diabetes

Advanced Care Decision Aids Underutilized

Higher Risk of Vascular Events With Polymyalgia Rheumatica CME

Large Variation in Lipid Reduction With High-Dose Statin Tx

CDC Issues Travel Warning As Africa Ebola Outbreak Worsens

FDA Approves Once-Daily, Long-Acting Inhaler for COPD